Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."


TSX:TST - Post by User

Bullboard Posts
Post by conspiTheoryon Jun 09, 2011 8:18pm
280 Views
Post# 18696440

saw bioniche ad ~ 13:15 on BNN

saw bioniche ad ~ 13:15 on BNNand that to:

Takeda Pharmaceutical Co.’s best- selling drug, Actos for diabetes, will be pulled from the French market after a study showed it carried a slightly increased risk of bladder cancer, the country’s drug regulator said.

Patients taking the treatment shouldn’t stop without consulting their physician, the regulator, known as Afssaps, said in a statement on its website. Doctors should no longer prescribe the drug, the agency said after holding a meeting today to consider the medicine’s risks and benefits.

Actos, also known as pioglitazone, had sales of 387.9 billion yen ($4.8 billion) in the last fiscal year, accounting for 27 percent of Osaka, Japan-based Takeda’s revenue. The drug was approved in Europe in 2000 as an option for patients who didn’t benefit from metformin, a standard treatment, or for those also taking metformin or insulin. About 230,000 patients in France use Actos, Afssaps said.

https://www.bloomberg.com/news/2011-06-09/takeda-s-actos-drug-suspended-in-france-on-cancer-risk-study-3-.html

Bullboard Posts